問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Link to Hospital

  • 1,089

    Total Beds

  • 275

    Total Doctors

  • shengyuan@cgmh.org.tw
  • Lin, Sheng-yuan
  • 02-24329292 #2082
  • 204Keelung CityAn LeNo. 222, Maijin Rd., Anle Dist., Keelung City 204015, Taiwan

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

167Cases

2015-09-15 - 2019-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

林振源
China Medical University Hospital-Taipei

未分科

2022-01-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2012-04-01 - 2014-04-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-06-01 - 2027-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-02-01 - 2028-01-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2019-04-08 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-05-31 - 2027-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2024-11-01 - 2026-03-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2021-01-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2024-07-01 - 2027-12-31

Phase III

Active
Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    placebo ‧ BI 690517 Empagliflozin

Participate Sites
23Sites

Recruiting23Sites

1 5 6 7 8 9 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB